Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Common Equity (2020 - 2025)

Rapid Micro Biosystems' Common Equity history spans 6 years, with the latest figure at $33.2 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 55.93% to $33.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $33.2 million, a 55.93% decrease, with the full-year FY2025 number at $33.2 million, down 55.93% from a year prior.
  • Common Equity hit $33.2 million in Q4 2025 for Rapid Micro Biosystems, down from $44.3 million in the prior quarter.
  • Over the last five years, Common Equity for RPID hit a ceiling of $234.7 million in Q3 2021 and a floor of -$164.5 million in Q2 2021.
  • Historically, Common Equity has averaged $99.1 million across 5 years, with a median of $112.0 million in 2023.
  • The widest YoY moves for Common Equity: up 306.25% in 2021, down 59.38% in 2021.
  • Tracing RPID's Common Equity over 5 years: stood at $221.0 million in 2021, then dropped by 25.71% to $164.2 million in 2022, then decreased by 28.13% to $118.0 million in 2023, then plummeted by 36.14% to $75.4 million in 2024, then tumbled by 55.93% to $33.2 million in 2025.
  • Business Quant data shows Common Equity for RPID at $33.2 million in Q4 2025, $44.3 million in Q3 2025, and $54.5 million in Q2 2025.